Abstract:Elder patients with non-small cell lung cancer (NSCLC) have been habitually underrepresented in clinical trails. Retrospective analysis have shown similar therapeutic outcome of platinum-based combined chemotherapy for fit elderly, albeit more toxicity compared with younger coun-terparts. Gefitinib, an oral EGFR-TKI was generally well tolerated with clinically meaningful anti-tumor activity in previously treated patients as well as chemo-naïve patients. The aim of the study was to retrospectively evaluate the toxicity, efficacy and survival of gefitinib versus platinum-based combined chemotherapy as first-line treatment for a series of Chinese patients aged 70 and over with advanced NSCLC. from January 2002 to December 2005, 38 patients received chemotherapy (17 of Novelbine, 8 of Gemcitabine, 7 of taxol and 7 of taxotere, all of which combined with cisplatin or carboplatin) and 17 patients received gefitinib 250mg once daily as first line treatment. Of the 38 patients who received chemotherapy, the median age was 73.3 years old (70-80) with 68.4% male, 73.7% adenocarcinoma and 78.9% patients were in stage 4. The PS of all patients was 0-1. Of the 17 patients who received gefitinib, the median age was 76.9 years old (70-85) with 58.8% male, 64.7% adenocarcinoma and 82.4% patients were in stage 4. The PS of 6 patients was over 2. The most frequently reported adverse events for chemotherapy group were neutropenia (92.1%) and thrombocytopenia(73.7%). Grade 3/4 neutropenia was 21.1% and four patients had nertropenia febril. Grade 3/4 thrombocytopenia was 10.5% and 2 patients need blood transfusion. Other grade 3/4 adverse effects included 3 cases of vomiting and one case of cardiac arrhythmia. 4 patients withdrew the chemotherapy due to side effects. The most frequently reported adverse events for gefitinib group were skin disorders (70.6%) and diarrhea (35.3%). The majority of these events were mild with grade 1 to grade 2. One patient was hospitalization due to grade 3 diarrhea and recovered without drug administration disruption. Other adverse events included 2 cases of nausea, 1 case of oral ulcer and 1 case of elevation in hepatic enzymes. No patient withdrew due to adverse effect. The par-tial response and disease control rate were 21.1% and 78.9% for chemotherapy group versus 17.6% and 68.8% for gefitinib group. The median progress free survival and overall survival time were 4.93 ± 0.747 months (95% CI: 3.465, 7.395) and 13.882 ± 0.718 months (95% CI: 12.892, 20.708) for chemotherapy group versus 6.4 ± 1.852 months (95%CI: 2.770, 10.030) and 15.882 ± 2.029 months (95%CI: 13.654, 20.505). The one-year survival was 52.6% in chemotherapy group versus 47.1% in gefitinib group. There is no statisti-cal significance between the two groups for efficacy, progress free survival time and overall survival time. Platinum-based combined chemotherapy was well tolerated and provides significant anti-tumor activity in elder patients. Gefitinib as first-line treatment provides similar clinical benefit with less toxicity for the elder NSCLC patients.

Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer]

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

Clinical study of pemetrexed combined with carboplatin as the first-line treatment of senile patients with advanced non-squamous non-small cell lung cancer

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Efficacy and Safety of First-Line Pemetrexed Plus Carboplatin Followed by Single-Agent Pemetrexed Maintenance in Elderly Chinese Patients with Non-Squamous Non-Small-cell Lung Cancer

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

Clinical observation of pemetrexed plus carboplatin as the first-line chemotherapy in elderly patients with advanced lung adenocarcinoma

Paclitaxel combined with carboplatin in the treatment of elderly and younger patients with advanced non-small cell Lung cancer

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Clinical observation of efficacy and safety of pemetrexed plus platinum as the first-line chemotherapy with advanced non-squamous non-small cell lung cancer

Pemetrexed and Platinum As First-Line Chemotherapy for Advanced Lung Adenocarcinoma:An Observation of Recent Therapeutic Effects and a Safety Profile

Efficacy and Safety of Pemetrexed Compared with Docetaxel As Second-Line Treatment in Elderly Patients with Advanced Non-Squamous Non-Small-cell Lung Cancer

Pemetrexed Combined with Carboplatin in Second-line Treatment of 56Elderly Patients with Advanced Pulmonary Adenocarcinoma

[Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

Pemetrexed Combined with Cisplatin in Treating 38 Cases of Elderly Advanced Non-Small Cell Lung Cancer

Phase II Trial of a 2-Hour Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

P3-163: Gefitinib versus chemotherapy as first-line treatment in elder patients with advanced non-small-cell lung cancer

Pemetrexed Monotherapy Versus Pemetrexed Plus Platinum Combination As Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

Vinorelbine versus vinorelbine-carboplatin in treatment of elderly patients with advanced non-small cell lung cancer

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (>= 75 Years Old) With Non-Small-Cell Lung Cancer